Climb Bio (CLYM) Equity Ratio (2020 - 2026)
Climb Bio filings provide 7 years of Equity Ratio readings, the most recent being 0.97 for Q1 2026.
- Quarterly Equity Ratio rose 0.88% to 0.97 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.97 through Mar 2026, up 0.88% year-over-year, with the annual reading at 0.96 for FY2025, 1.94% down from the prior year.
- Equity Ratio hit 0.97 in Q1 2026 for Climb Bio, up from 0.96 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.98 in Q3 2024 and bottomed at 0.95 in Q2 2022.
- Average Equity Ratio over 5 years is 0.97, with a median of 0.97 recorded in 2023.
- The largest annual shift saw Equity Ratio surged 300.58% in 2022 before it dropped 1.94% in 2025.
- Climb Bio's Equity Ratio stood at 0.95 in 2022, then grew by 2.15% to 0.97 in 2023, then grew by 0.16% to 0.98 in 2024, then dropped by 1.94% to 0.96 in 2025, then increased by 1.59% to 0.97 in 2026.
- Per Business Quant, the three most recent readings for CLYM's Equity Ratio are 0.97 (Q1 2026), 0.96 (Q4 2025), and 0.97 (Q3 2025).